GAMMA Investing LLC Has $1.66 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• GAMMA Investing LLC has reduced its holdings in Thermo Fisher Scientific by 15.7%, now owning 4,100 shares valued at approximately $1.66 million.
• Thermo Fisher Scientific reported a quarterly EPS of $5.36, exceeding analysts' expectations, and expects a quarterly EPS guidance of 5.460-5.510 for Q3 2025.
• The company is set to pay a quarterly dividend of $0.43 per share on October 15th, with a dividend yield currently at 0.4%.

GAMMA Investing LLC reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 15.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,100 shares of the medical research company's stock after selling 762 shares during the quarter. GAMMA Investing LLC's holdings in Thermo Fisher Scientific were worth $1,662,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of TMO. Bernard Wealth Management Corp. acquired a new position in Thermo Fisher Scientific during the 4th quarter worth $25,000. CBIZ Investment Advisory Services LLC lifted its holdings in Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after buying an additional 33 shares in the last quarter. Ameriflex Group Inc. acquired a new position in Thermo Fisher Scientific during the 4th quarter worth $30,000. Anderson Financial Strategies LLC acquired a new position in Thermo Fisher Scientific during the 1st quarter worth $30,000. Finally, Keystone Global Partners LLC bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at $31,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Down 1.1%

Thermo Fisher Scientific stock opened at $474.54 on Tuesday. The firm has a 50-day moving average of $472.99 and a 200-day moving average of $448.55. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $623.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The company has a market cap of $179.19 billion, a price-to-earnings ratio of 27.45, a P/E/G ratio of 2.56 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the prior year, the business posted $5.37 EPS. The company's quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is currently 9.95%.

Wall Street Analysts Forecast Growth

TMO has been the subject of several recent research reports. Wells Fargo & Company dropped their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Robert W. Baird upped their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. William Blair initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They set an "outperform" rating for the company. UBS Group upped their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. Finally, HSBC reiterated a "hold" rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific has an average rating of "Moderate Buy" and a consensus price target of $588.35.

Insider Transactions at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the sale, the chief executive officer owned 115,174 shares of the company's stock, valued at $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock worth $14,182,963 in the last three months. Insiders own 0.33% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.